When you hand your insurance card to the pharmacist and pay a $10 copay for a 30-day supply of atorvastatin, you probably assume you are getting the best available price. You are not. In 2025, the pharmacy benefit manager (PBM) ecosystem has created a system where cash prices for many generic drugs are lower than what most insured patients pay at the register. The culprit is a three-tiered pricing structure that benefits PBMs, pharmacy chains, and insurers — but rarely the patient. This article breaks down exactly how the markups work, which generic drugs are most overpriced through insurance, and a step-by-step method for cutting your monthly prescription costs by 50 to 80 percent without switching plans or reducing coverage.
The core mechanism is the PBM's "spread pricing" model. Your employer or insurer pays the PBM a negotiated rate for each prescription, and the PBM reimburses the pharmacy at a separate, lower rate. The difference, called the spread, is PBM profit. For generic drugs, where wholesale acquisition costs are low, the PBM reimburses pharmacies at rates tied to a benchmark called the National Average Drug Acquisition Cost (NADAC) plus a small markup — typically $1 to $3 per fill.
But here is where the patient loses: your copay is usually not tied to the pharmacy's actual acquisition cost. It is tied to a contracted "usual and customary" price that the pharmacy sets high enough to cover losses from brand-name drugs and third-party payer clawbacks. That $10 copay for metformin? The pharmacy may have bought the bottle for $1.50 and the PBM reimburses them $2.10. The insurance company bills your employer $12.00, the PBM keeps $9.90, and you pay $10. Meanwhile, the cash price at the same register without insurance is $7.00. You have just overpaid by 43 percent.
This is not a glitch. It is the design. PBMs have created a system where cash prices are voluntarily suppressed by pharmacies to drive uninsured patients away from paying cash, while insured patients are billed through opaque formularies that hide the true cost.
Data from the 2024 Milliman Medical Index on prescription drug pricing reveals three categories where the cash-vs-copay gap is widest and most consistent across all 50 states and all major PBM networks (Express Scripts, OptumRx, Caremark).
Atorvastatin 20mg (generic Lipitor) costs $1.80 per 30-tablet bottle at wholesale. Most insurance copays for tier 1 generics run $8 to $15 per month. Cash price at major chains: $6.00 at Costco, $7.50 at Walmart, $8.00 at Kroger. Even after factoring in the $30 annual Costco membership ($2.50 per month), paying cash for a twelve-month supply saves $54 versus a $10 copay. The gap widens when you use a free cash-pay discount card like GoodRx, which negotiates directly with pharmacies to bring that $8.00 price down to $4.00 in 2025.
Lisinopril 10mg, one of the most prescribed drugs in America, has a wholesale cost of $0.90 for a 30-day supply. Insurance copay tiers for this and most ACE inhibitors run $8 to $12. Cash price at Costco without insurance: $4.68. With a GoodRx coupon: $2.55. The annual difference between paying a $10 copay and using a cash-pay discount card is $89.40 — on just one medication. For a patient taking three common generics (statin, ACE inhibitor, and a beta-blocker), the annual overpayment through insurance copays can exceed $300.
Escitalopram (generic Lexapro) 20mg has a wholesale cost of $3.60 per 30-day fill. Insurance formularies often place this on tier 2, not tier 1, meaning copays of $20 to $35. Cash price without insurance: $15 at Target, $12 at Costco. The cash-pay card rate through SingleCare or GoodRx for this drug averages $6.78 in 2025. That is a monthly savings of $13.22 to $28.22 versus a $20 copay — or $158 to $338 annually for one medication.
Smartphones have made this process fast enough to do while you are waiting at the drop-off window. Here is the system that personal finance bloggers recommend and that actually works without violating any terms of service.
This strategy has one important edge case. In rural areas where the nearest pharmacy is a single independent store without competition, cash prices can be 30 to 50 percent higher than urban pharmacies because of lower volume and higher wholesale acquisition costs from small distributors. If you live in a pharmacy desert — defined by the HRSA as an area with fewer than one pharmacy per 10,000 residents — your cash price for generic gabapentin might be $18 versus an insurance copay of $10. Here, your insurance copay actually saves you $8.
The fix is mail-order. Most PBMs offer a 90-day mail-order option that charges a standard tier 1 copay, typically $5 to $10 for generics, with free shipping. For rural patients, this beats both the local cash price and the in-store insurance copay. CVS Caremark's mail-order service, for example, charges $8 for a 90-day supply of metformin, whereas the same drug in a rural independent pharmacy costs $22 cash or $12 with insurance. Mail-order saves you $4 per fill versus the in-store copay, and $14 versus the cash price.
Individual patients rarely realize that their out-of-pocket cost is determined not by the drug's actual cost, but by their employer's specific PBM contract. Large employers with over 5,000 employees can negotiate flat copay structures that are lower than standard PBM offerings. Employers with fewer than 200 employees often have no negotiating power and are stuck with the PBM's default tier structure, which sets generic copays at $15 to $20 regardless of the drug's wholesale cost.
If you work for a small to mid-sized company, you are paying higher copays than employees at Fortune 500 companies for the same generic drugs. This is not speculation — the Kaiser Family Foundation's 2024 Employer Health Benefits Survey shows that workers in firms with fewer than 200 employees pay an average of $17.80 for generic tier 1 drugs, while workers in firms with 5,000+ employees pay $9.10. That $8.70 per fill difference, applied to 6 generic prescriptions per month (average for adults over 45 with hypertension, diabetes, and cholesterol management), totals $626.40 per year in excess costs that are invisible because your employer's HR department cannot legally tell you that you are paying more than another company's employees for the same medication.
As of January 2025, 14 states have enacted laws requiring pharmacies to disclose the cash price of any generic drug before processing insurance, if the patient requests it. These states include California, New York, Texas, Florida, Illinois, Ohio, Pennsylvania, Michigan, North Carolina, Georgia, Virginia, Washington, Colorado, and Arizona. If you live in one of these states, you are legally entitled to hear the cash price before the pharmacist runs your insurance. In states without such laws, the pharmacist can legally refuse to disclose the cash price until after insurance is processed, which effectively locks you into the higher copay.
For residents in non-disclosure states, the workaround is simple: ask the pharmacist, "What is the cash price for 30 tablets of this medication? I am not authorizing insurance processing yet." Most pharmacists will answer, but they are not required to in those states. If they refuse, walk to the next pharmacy. The time cost is worth the $40 per month you will save on a three-drug regimen.
The second relevant law is the 2023 FDA guidance on "accumulation of generic drug price data," which now requires manufacturers to report wholesale prices quarterly to the NADAC database. This has made cash price comparisons more reliable because the baseline is public. You can check the NADAC price for any generic drug at medicaid.gov/nadac while in line at the pharmacy. Cross-reference it with the pharmacy's recent cash price. If the pharmacy is charging more than 50 percent above NADAC, file a complaint with your state's board of pharmacy.
This article focuses on generics, but brand-name drugs with no generic equivalent follow a completely different financial logic. Many manufacturers offer patient assistance programs (PAPs) that provide the drug for free to patients earning up to 400 percent of the federal poverty level. For a single person in 2025, that is an annual income ceiling of approximately $60,000. PAPs cover drugs like Humira, Jardiance, and Keytruda. If you are on a brand-name drug that costs $1,500 per month with insurance, your cash price will be even higher, but the PAP coupon from the manufacturer can bring your out-of-pocket to $0.
The trap here is that most insurance formularies require you to try a generic first (step therapy) before approving the brand-name drug. If you find that the generic is too expensive even with a cash-pay card, and you have a brand-name drug on your regimen, call the manufacturer directly and ask for their copay assistance program. Do this before filling the prescription, because some programs require pre-approval.
For the vast majority of people taking only generics — which accounts for 90 percent of all prescriptions filled in the U.S. — the cash-pay card strategy is simpler, faster, and more profitable. You can test it on your next fill. Keep your insurance card in your wallet. Pull up GoodRx on your phone. Ask for the cash price with the code. If the total is lower than your copay, pay cash and save the receipt. Your insurance plan will not penalize you for paying cash because you are not filing a claim. This is not insurance fraud — it is the most direct path to paying what the drug actually costs.
Browse the latest reads across all four sections — published daily.
← Back to BestLifePulse